Brief: Santen and Tracon announce initiation of a phase 2a study of drug for the treatment of wet age-related macular degeneration

SANTEN PHARMACEUTICAL

26/07/2017 01:00

July 25 (Reuters) - Tracon Pharmaceuticals Inc  TCON.O  
    * Santen and Tracon announce initiation of a phase 2a study 
of DE-122 for the treatment of wet age-related macular 
degeneration 
    * Initiation of phase 2a study triggers a $7 million 
milestone payment from Santen to Tracon 
 
Source text for Eikon:  ID:nGNXOCOKSa  
Further company coverage:  TCON.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))